InCrowd Industry Highlights for Pharma Market Researchers:

This edition highlights biopharma industry predictions, lessons learned from pharma social listening project, mobile tools and services, cost of new drug development and a few possibilities around the FDA’s social media rules coming this summer:

– Expect Bold Moves in the Biopharma Industry in 2013 from FierceBiotech offers five predictions about how they think things will play out in the biopharma industry during the upcoming year

– Ragan’s Health Care Communication News shares lessons learned when no one is talking about your brand during a yearlong social listening project by DKI Healthcare Relationship Marketing in Social Listening for Pharma Relationship Marketing

– This year patients, prescribers and the public increasingly turned to their mobile devices. PMLiVE’s Pharma’s 2012 … Going Mobile outlines the pharma mobile device tools and services developed during 2012

– The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The Truly Staggering Cost Of Inventing New Drugs from Forbes includes a chart on drug company research spending per new drug

– Pharmalot’s The Op-Ed: FDA Really Will Issue Social Media Rules looks at three possibilities for FDA social media rules and guidelines, that per a provision in the FDA reform bill passed last summer should be in place by July 9, 2014

That wraps this week’s review of news from and for the pharma market research community. I’ll leave you with an invitation to learn more about the benefits of real time data and offer you a personal demo of InCrowd’s on-demand platform  providing you direct and immediate access to Crowds of screened and targeted healthcare professionals.

If you have tips, suggestions, or resources you’d like to share leave us a comment below and please feel free to suggest topics that you would like to see covered in future posts.